BR112021023241A2 - Forma cristalina de brometo de sofpironium e método de preparação da mesma - Google Patents

Forma cristalina de brometo de sofpironium e método de preparação da mesma

Info

Publication number
BR112021023241A2
BR112021023241A2 BR112021023241A BR112021023241A BR112021023241A2 BR 112021023241 A2 BR112021023241 A2 BR 112021023241A2 BR 112021023241 A BR112021023241 A BR 112021023241A BR 112021023241 A BR112021023241 A BR 112021023241A BR 112021023241 A2 BR112021023241 A2 BR 112021023241A2
Authority
BR
Brazil
Prior art keywords
crystalline form
preparation
sofpironium bromide
sofpironium
bromide
Prior art date
Application number
BR112021023241A
Other languages
English (en)
Portuguese (pt)
Inventor
R Brinkman Herbert
Kazuyoshi MARUBAYASHI
Masahito Watanabe
Original Assignee
Brickell Biotech Inc
Kaken Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brickell Biotech Inc, Kaken Pharma Co Ltd filed Critical Brickell Biotech Inc
Publication of BR112021023241A2 publication Critical patent/BR112021023241A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/147Saturated compounds having only one carboxyl group and containing —CHO groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112021023241A 2019-05-23 2020-05-22 Forma cristalina de brometo de sofpironium e método de preparação da mesma BR112021023241A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851880P 2019-05-23 2019-05-23
PCT/JP2020/020210 WO2020235665A1 (en) 2019-05-23 2020-05-22 Crystalline form of sofpironium bromide and preparation method thereof

Publications (1)

Publication Number Publication Date
BR112021023241A2 true BR112021023241A2 (pt) 2022-01-04

Family

ID=72146250

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023241A BR112021023241A2 (pt) 2019-05-23 2020-05-22 Forma cristalina de brometo de sofpironium e método de preparação da mesma

Country Status (18)

Country Link
US (3) US20220298108A1 (https=)
EP (1) EP3972955A4 (https=)
JP (2) JP6748329B1 (https=)
KR (1) KR20220011671A (https=)
CN (1) CN114008023B (https=)
AU (1) AU2020277881B2 (https=)
BR (1) BR112021023241A2 (https=)
CA (1) CA3139948A1 (https=)
CL (1) CL2021003047A1 (https=)
CO (1) CO2021017456A2 (https=)
IL (1) IL288285B1 (https=)
MX (1) MX2021014163A (https=)
MY (1) MY206154A (https=)
PH (1) PH12021552915A1 (https=)
SG (1) SG11202111678WA (https=)
TW (2) TWI838531B (https=)
WO (1) WO2020235665A1 (https=)
ZA (1) ZA202109514B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3972955A4 (en) * 2019-05-23 2023-07-05 Kaken Pharmaceutical Co., Ltd. CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND ASSOCIATED METHOD OF PREPARATION
EP4213158A1 (en) 2020-11-13 2023-07-19 Ahead Biocomputing, Co. Ltd Information processing device, information processing method, recording medium recording information processing program, and information processing system
CN115925603B (zh) * 2022-11-29 2025-07-22 山东齐都药业有限公司 索吡溴铵的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
ATE529399T1 (de) * 2005-11-10 2011-11-15 Nicholas S Bodor Sanfte anticholinerge ester
ATE529400T1 (de) * 2005-11-10 2011-11-15 Nicholas S Bodor Weiche anticholinerge zwitterionen
MX357741B (es) * 2012-07-06 2018-07-23 Laboratorios Senosiain S A De C V Star Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5.
US9512166B2 (en) * 2012-09-05 2016-12-06 Amri Ssci, Llc Cocrystals of progesterone
US20150259283A1 (en) * 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
US10282282B2 (en) * 2016-06-29 2019-05-07 Synopsys, Inc. Automated HTTP user flows simulator
WO2018026869A1 (en) * 2016-08-02 2018-02-08 Dermira, Inc. Processes for making, and methods of using, glycopyrronium compounds
EP3972955A4 (en) * 2019-05-23 2023-07-05 Kaken Pharmaceutical Co., Ltd. CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND ASSOCIATED METHOD OF PREPARATION

Also Published As

Publication number Publication date
CA3139948A1 (en) 2020-11-26
IL288285B1 (en) 2026-02-01
CN114008023A (zh) 2022-02-01
US20210395197A1 (en) 2021-12-23
AU2020277881B2 (en) 2025-03-06
CO2021017456A2 (es) 2022-01-17
WO2020235665A1 (en) 2020-11-26
MX2021014163A (es) 2022-01-04
ZA202109514B (en) 2023-12-20
PH12021552915A1 (en) 2022-04-04
SG11202111678WA (en) 2021-11-29
US20220298108A1 (en) 2022-09-22
JP7605598B2 (ja) 2024-12-24
CN114008023B (zh) 2024-02-09
US11584715B2 (en) 2023-02-21
EP3972955A1 (en) 2022-03-30
MY206154A (en) 2024-12-02
CL2021003047A1 (es) 2022-09-20
IL288285A (en) 2022-01-01
AU2020277881A1 (en) 2021-12-09
JP6748329B1 (ja) 2020-08-26
TWI870116B (zh) 2025-01-11
TW202411205A (zh) 2024-03-16
TWI838531B (zh) 2024-04-11
US20210171460A1 (en) 2021-06-10
JP2020189839A (ja) 2020-11-26
EP3972955A4 (en) 2023-07-05
JP2020189856A (ja) 2020-11-26
KR20220011671A (ko) 2022-01-28
TW202110796A (zh) 2021-03-16
US11566000B2 (en) 2023-01-31

Similar Documents

Publication Publication Date Title
BR112021023241A2 (pt) Forma cristalina de brometo de sofpironium e método de preparação da mesma
PH12021552083A1 (en) Fused tricyclic compounds useful as anticancer agents
MX2022003032A (es) Oxinitruro de piridina, metodo para su preparacion y uso de este.
BG108318A (en) Carboxamide-substituted phenylurea derivatives and method for the production and use thereof as medicaments
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
UY28482A1 (es) Nuevos compuestos
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
MY209603A (en) Hydroxypyridoxazepines as nrf2 activators
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12020551256A1 (en) Salts, crystal forms, and production methods thereof
CY1113339T1 (el) Ιμιδαζοκινολινες με ανοσο-ρυθμιστικες ιδιοτητες
GEP20094664B (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
ES2158814B1 (es) Derivados de pirrolidina antagonistas del receptor ccr-3
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
MY143565A (en) Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
CR10056A (es) [(1h-indol-5-il)-heteroariloxi]-(1-aza-biciclo[3.3.1]nonanos como ligandos colinérgicos del n-achr para el tratamiento de trastornos piscóticos y neurodegenerativos
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
AR080803A1 (es) Derivados de 3,4-dihidro-1h-benzo[b][1,6]naftiridina, composiciones farmaceuticas que los contiene, procedimiento para prepararlos e intermediarios del mismo, y uso de los compuestos en el tratamiento de canceres y enfermedades autoinmunes e inflamatorias.
WO2012004714A3 (en) Benzene sulfonamides as inhibitors of voltage-gated sodium channels
PL2227476T3 (pl) Tricykliczne związki triazolowe
SE0401762D0 (sv) Novel compounds
CR20210216A (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
GT200500107A (es) Derivados de fenol y tiofenol 3-0 4-monosustituidos utiles como ligandos de h3
MY135850A (en) Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
BR112022001568A2 (pt) Composto, método para preparação do composto, composição farmacêutica, e, uso do composto

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]